Literature DB >> 18163500

Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare?

Spyros Aslanidis1, Athina Pyrpasopoulou, Stella Douma, Konstantinos Petidis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18163500     DOI: 10.1002/art.23210

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  5 in total

1.  Tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient on anti-TNFα therapy for Crohn's disease.

Authors:  Caroline O'Dowd; Peter Kewin; John Morris; Mark Cotton
Journal:  BMJ Case Rep       Date:  2011-03-08

Review 2.  Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Clin Rheumatol       Date:  2011-12-15       Impact factor: 2.980

3.  Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Authors:  Yesim Ozguler; Gulen Hatemi; Serdal Ugurlu; Emire Seyahi; Melike Melikoglu; Sermin Borekci; Ersan Atahan; Gul Ongen; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2016-10-03       Impact factor: 2.631

Review 4.  Lethal disseminated tuberculosis in patients under biological treatment - two clinical cases and a short review.

Authors:  Elena Dantes; Doina Ecaterina Tofolean; Ariadna Petronela Fildan; Liviu Craciun; Elena Dumea; Ioan Tiberiu Tofolean; Laura Mazilu
Journal:  J Int Med Res       Date:  2018-05-23       Impact factor: 1.671

5.  Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.

Authors:  Young Sun Suh; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park; Chong-Hyeon Yoon
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.